Pharma Giants and AI Disruptors: Top Healthcare Growth Stocks for 2026
Key Takeaways
- Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure.
- Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.
Mentioned
Key Intelligence
Key Facts
- 1Eli Lilly's tirzepatide became the world's best-selling drug in 2025.
- 2SoundHound AI reported a 59% revenue increase in the fourth quarter of 2025.
- 3Nebius projects its Annual Run Rate (ARR) to grow from $1.25B to between $7B and $9B by year-end 2026.
- 4Eli Lilly is expected to launch orforglipron, an oral GLP-1 drug, during 2026.
- 5SoundHound AI stock is currently trading approximately 60% below its all-time high.
| Company | ||
|---|---|---|
| Eli Lilly | Obesity/Diabetes (GLP-1) | Launch of oral orforglipron |
| Veeva Systems | Life Sciences Cloud SaaS | Steady expansion of R&D suite |
| SoundHound AI | Generative Voice AI | Expansion into medical/insurance admin |
| Nebius | AI Infrastructure | Projected 600%+ ARR growth |
Analysis
The healthcare sector in early 2026 is being reshaped by a powerful convergence of metabolic medicine and advanced artificial intelligence. While broader equity markets have exhibited significant volatility, the underlying fundamentals for select growth stocks in the pharmaceutical and health-IT sectors remain robust. At the center of this transformation is Eli Lilly, which has transitioned from a traditional pharmaceutical giant into a high-growth powerhouse that more closely resembles a scaling technology firm. This shift is primarily fueled by the unprecedented success of tirzepatide, which secured its position as the world's best-selling drug in 2025. The company's trajectory is set to accelerate further in 2026 with the anticipated launch of orforglipron, an oral GLP-1 agonist that could democratize weight-loss treatment by removing the barrier of injectable administration.
Beyond the immediate success of obesity treatments, the industry is witnessing a structural shift in how life sciences companies operate. Veeva Systems continues to serve as the critical digital infrastructure for the sector, providing the cloud-based tools necessary for clinical trials, regulatory compliance, and commercialization. As pharmaceutical companies like Eli Lilly invest more heavily in AI-powered drug discovery, the demand for Veeva’s integrated data platforms becomes even more pronounced. This 'picks and shovels' play offers a more stable growth profile compared to the binary outcomes of drug development, making it a cornerstone for healthcare-focused portfolios in 2026.
With an annual run rate (ARR) projected to leap from $1.25 billion at the end of 2025 to as much as $9 billion by the end of 2026, the demand for specialized AI computing power is clearly outstripping supply.
The integration of AI is not limited to the laboratory. A new wave of 'red-hot' growth stocks is targeting the massive administrative inefficiencies that plague the healthcare system. SoundHound AI, despite recent market pullbacks, is making significant inroads into medical and insurance customer service. By combining audio recognition with generative AI, the company aims to automate high-cost administrative interactions that have traditionally required human intervention. While its current success is most visible in restaurant drive-thru automation, the scalability of its voice AI into the medical sector represents a massive untapped market. For healthcare institutions, the ability to automate patient scheduling, insurance inquiries, and basic triage could lead to substantial operational cost reductions.
What to Watch
Investors are also closely monitoring hyper-growth entities like Nebius, which is operating in the critical AI infrastructure space. With an annual run rate (ARR) projected to leap from $1.25 billion at the end of 2025 to as much as $9 billion by the end of 2026, the demand for specialized AI computing power is clearly outstripping supply. This infrastructure is the backbone upon which the next generation of healthcare AI—from diagnostic imaging to personalized medicine—will be built. As we move through the first half of 2026, the key for market participants will be distinguishing between companies with speculative AI narratives and those, like Eli Lilly and Veeva, that are delivering tangible financial results and market-leading products.
Looking forward, the second half of 2026 will likely be defined by the clinical data readouts of next-generation oral GLP-1s and the real-world efficacy of generative AI in reducing healthcare overhead. The volatility seen in early 2026 may provide entry points for long-term investors, but the focus must remain on companies that can navigate regulatory hurdles while maintaining double-digit top-line growth. The healthcare sector is no longer just a defensive play; it has become one of the primary engines of global innovation and capital appreciation.
Sources
Sources
Based on 2 source articles- Prosper Junior Bakiny (us)2 Top Growth Stocks to Buy in the First Half of 2026Mar 4, 2026
- Keithen Drury (us)3 Red-Hot Growth Stocks to Buy in 2026Mar 4, 2026